At Texas Retina, we remain committed to participating in clinical trials that provide our patients access to promising treatments for a variety of retina conditions, including age-related macular degeneration (AMD), ocular melanoma (cancer), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and uveitis.
Conducting ongoing research that advances retinal care is a value that was instilled by the pioneering physicians who founded our practice more than 50 years ago. Over time, this work has helped lead to new sight-saving treatments for diseases that once robbed patients of their vision.
We recently opened three new clinical trials at our Dallas Main office:
Diabetic Macular Edema
Thulite – 1485-0018 — A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema (DME).
Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Roche BP45482 — A Phase I, multi-center, multi-part study to investigate safety, tolerability, pharmokinetics (PK), pharmacodynamics (PD), and immunogenicity of RO7669330 intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Wet Macular Degeneration
4FRONT-2 — A Phase III, randomized, double-masked, active-controlled trial of a single intravitreal injection of 4D-150 in adults with macular neovascularization secondary to age-related macular degeneration (AMD).
We currently have a total of 24 open studies. Click here to view all of our actively enrolling clinical trials.
For more information or to determine eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.